Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord Wharton's jelly-derived human mesenchymal stromal cells
- Development stage
- Phase 2
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord Wharton's jelly-derived human mesenchymal stromal cells (UC-MSC) is an investigational cell therapy developed by Assistance Publique - Hôpitaux de Paris (AP-HP). These cells are harvested from the Wharton's jelly of the human umbilical cord and are characterized by their high production of bioactive molecules and potent immunomodulatory, anti-inflammatory, and anti-fibrotic properties. The therapy is primarily being evaluated for the treatment of Acute Respiratory Distress Syndrome (ARDS), specifically in the context of SARS-CoV-2 infection. By modulating the immune response and reducing pulmonary inflammation, UC-MSCs aim to improve oxygenation and accelerate recovery in critically ill patients. The cells can be scaled up into cryopreserved banks for ready availability and have demonstrated a favorable safety profile in clinical settings.
- Other names
- umbilical cord Wharton's jelly-derived human mesenchymal stromal cellsWharton's jelly-derived mesenchymal stromal cellsumbilical cord Wharton's jelly-derived mesenchymal stromal cells (AP-HP)
Beyond the preview
Go deeper on umbilical cord Wharton's jelly-derived human mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord Wharton's jelly-derived human mesenchymal stromal cells.